Clinical Trials on Primary Dyslipidemia

Total 61941 results

GlaxoSmithKline

Completed

GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol

Dyslipidaemia | Dyslipidaemias

Germany, Estonia, Belgium, France, Netherlands, Denmark, Portugal, Norway, Sweden, Lithuania, Finland
GlaxoSmithKline

Completed

Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.

Healthy Subjects | Dyslipidaemia | Dyslipidaemias

United Kingdom
Xention Ltd

Completed

Study of the Electrocardiographic Effects of TA-8995

Dyslipidaemia

United Kingdom
AstraZeneca

Completed

Statin Therapy Results in the Real World Practice in the Czech Republic (STEP)

Dyslipidaemia

Czech Republic
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia

Dyslipidaemia

Denmark, United States, Slovakia
Novartis Pharmaceuticals

Completed

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Dyslipidaemia

Jordan, United States, Taiwan
AstraZeneca

Completed

48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

Dyslipidaemia
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Dyslipidemias | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

Dyslipidaemias

United States, Canada
Novo Nordisk A/S

Recruiting

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Healthy Volunteers | Dyslipidaemia

United States
AstraZeneca

Completed

Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

Dyslipidaemia

Russian Federation
AstraZeneca

Completed

Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS) (IRIS)

Hypercholesterolemia | Dyslipidaemia
GlaxoSmithKline

Completed

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

Dyslipidaemias

United States
GlaxoSmithKline

Completed

Study to Test GSK256073 in Patients With Dyslipidemia

Dyslipidemias | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects

Dyslipidaemias

United States
AstraZeneca

Completed

Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP) (STARSHIP)

Hypercholesterolemia | Dyslipidaemia
AstraZeneca

Completed

CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II) (CEPHEUSII)

Dyslipidaemia

Russian Federation
Xention Ltd

Completed

Bioequivalence Study of Capsule and Tablet Formulations of TA-8995

Dyslipidaemia

United Kingdom
AstraZeneca

Completed

Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES) (ARIES)

Hypercholesterolemia | Dyslipidaemia
GlaxoSmithKline

Completed

A Second Study to Determine the Effect of GSK256073A on HVTs

Healthy Subjects | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers

Healthy Subjects | Dyslipidaemias

United States
AstraZeneca

Completed

IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin

Fredrickson Type IIa & Type IIb Dyslipidaemia
NeuroBo Pharmaceuticals Inc.

Completed

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

Severe Hypertriglyceridemia | Mixed Dyslipidaemia

United States, Canada
Société des Produits Nestlé (SPN)

Completed

Effect of a Low Fat Milk Product on Lipids Profile in Dyslipidemia Subjects (Lipidown)

Primary Dyslipidemia

China
Kowa Research Institute, Inc.

Completed

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia (PREVAIL-US)

Mixed Dyslipidemia | Primary Dyslipidemia

United States
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Withdrawn

Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia (MILOS-Spain)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Amgen

Terminated

Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

Mixed Dyslipidemia | Primary Hypercholesterolemia

China
Amgen

Completed

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

Mixed Dyslipidemia | Primary Hypercholesterolemia

United States, Canada
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Novartis Pharmaceuticals

Recruiting

Study Evaluating Effectiveness and Adherence of Inclisiran Plus Standard of Care (SoC) Lipid-lowering Therapy Compared to SoC in ASCVD (VICTORION REAL)

Mixed Dyslipidemia | Primary Hypercholesterolemia

Switzerland, Saudi Arabia, United Arab Emirates, United Kingdom, Austria, Israel, China, Malaysia
Novartis Pharmaceuticals

Recruiting

Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Mixed Dyslipidemia | Primary Hypercholesterolemia

China
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Amgen

Completed

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Mixed Dyslipidemia | Primary Hypercholesterolemia

United States, Canada
Boryung Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

Mixed Dyslipidemia | Primary Hypercholesterolemia

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

MK-0524B Lipid Study (MK-0524B-063)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Primary Hypercholesterolaemia and Mixed Dyslipidemia

China
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. (V-Mono China)

Primary Hypercholesterolemia or Mixed Dyslipidemia

China
Orient Pharma Co., Ltd.

Completed

Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Primary Hypercholesterolemia | Mixed Dyslipidemias

Taiwan, Australia, New Zealand
Pfizer

Withdrawn

Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects (SPIRE-ASIA)

Primary Hyperlipidemia or Mixed Dyslipidemia

China
Amgen

Completed

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody (FLOREY)

Primary Hyperlipidemia and Mixed Dyslipidemia

Australia
University Health Network, Toronto
Canadian Institutes of Health Research (CIHR)

Completed

Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol

Insulin Resistance | Dyslipidaemia

Canada
GlaxoSmithKline

Completed

A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers

Healthy Subjects | Dyslipidaemias

United States
Sanofi

Completed

Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS)

Atherosclerotic Cardiovascular Disease | Primary Hypercholesterolaemia and Mixed Dyslipidaemia

Germany
GlaxoSmithKline

Completed

An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation

Obesity | Hypercholesterolemia | Dyslipidaemias

United States
GlaxoSmithKline

Terminated

Effect Of GW501516X On How The Heart Obtains And Uses Energy

Heart Failure | Dyslipidaemias

United States
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
Kowa Research Europe

Completed

Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels

Dyslipidemia | Primary Hypercholesterolemia

Spain, Denmark, India, Israel, Sweden, Finland, Germany, Italy, Netherlands, Norway, Poland, Russian Federation, United Kingdom
Genfit

Completed

Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity

Abdominal Obesity | Atherogenic Dyslipidaemia

France, Romania, Tunisia
Hanlim Pharm. Co., Ltd.

Recruiting

An Observational Study on the Identification of Prescription Patterns of STAFEN Cap

Mixed Dyslipidemia

Korea, Republic of

3

Subscribe